Difference between revisions of "Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study."

From OmniJournal
Jump to navigation Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.preprints.org/manuscript/202005.0...")
 
 
Line 25: Line 25:
 
== Major Issues ==
 
== Major Issues ==
  
No major issues identified.
+
No major issues identified at this time.
  
 
== Minor Issues ==
 
== Minor Issues ==
  
No minor issues identified.
+
No minor issues identified at this time.
  
 
== Impact ==
 
== Impact ==

Latest revision as of 17:05, 22 July 2020

Publication
Title
Authors
  • Francisco Membrillo
  • German Ramirez-Olivencia
  • Miriam Estebanez
  • ...
  • Lucia Ballester
Journal Preprints.org
Date May 6, 2020

Observational study in Spain of early treatment with hydroxychloroquine in 166 COVID-19 patients showed a significant survival benefit in patients started on hydroxychloroquine in the mild stage of disease.

Patients were categorized into one of three groups at initial presentation: mild, moderate or severe. There was a significant survival benefit in the mild group compared to controls (1.8 times, p = 0.032) and a trend toward survival benefit in the moderate and severe groups (1.4 times and 1.6 times, respectively). Of note, the average time between symptom onset and treatment was 7 days.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This is another retrospective analysis that suggests efficacy of early treatment with hydroxychloroquine against COVID-19.

Article Revisions

None at this time.

References